Anthony Browning
Psychiatric/Mental Health · Orem, UTNPI 1255588737
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,763 of the $31,761 with a category attached, or 81.1%. AbbVie accounts for 95.2% of it on its own, with 13 other manufacturers making up the rest. Among psychiatric/mental health clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $238.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Johnson & Johnson$468
- Otsuka America Pharmaceutical, Inc.$396
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$167
- Otsuka Pharmaceutical Development & Commercialization, Inc.$135
- E.r. Squibb & Sons, L.L.C.$99
- plus $269 from 8 others
What the payments were for
- Speaking & faculty fees$25,76381%
- Travel & lodging$3,22410%
- Food & beverage$2,7009%
- Education$740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 82 | $30,227 |
| Johnson & Johnson | 6 | $468 |
| Otsuka America Pharmaceutical, Inc. | 21 | $396 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $167 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $135 |
| E.r. Squibb & Sons, L.L.C. | 5 | $99 |
| Idorsia Pharmaceuticals US Inc | 1 | $68 |
| Vanda Pharmaceuticals Inc. | 3 | $59 |
| Lundbeck LLC | 4 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Alfasigma USA, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $11 |
| Alkermes, Inc. | 1 | $11 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,761 in reported general payments places this provider in the 95th percentile of 393 psychiatric/mental health providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 43 | $119,128 |
| VraylarCariprazine Hcl | 69 | $105,201 |
| IngrezzaValbenazine Tosylate | 13 | $87,482 |
| Invega SustennaPaliperidone Palmitate | 24 | $82,166 |
| AristadaAripiprazole Lauroxil | 19 | $67,502 |
| CaplytaLumateperone Tosylate | 23 | $37,091 |
| RexultiBrexpiprazole | 25 | $34,549 |
| TrintellixVortioxetine Hydrobromide | 62 | $28,982 |
| AuvelityDextromethorphan Hbr/Bupropion | 25 | $24,527 |
| ClozarilClozapine | 12 | $19,436 |
| Asenapine Maleate | 53 | $6,936 |
| Paliperidone ErPaliperidone | 66 | $5,442 |
| Buspirone Hcl | 206 | $3,647 |
| Clozapine | 46 | $3,126 |
| Duloxetine Hcl | 212 | $2,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $396 | $153,67768 claims |
| AbbVieVraylar | $30,227 | $105,20169 claims |
| Johnson & JohnsonInvega Sustenna | $468 | $82,16624 claims |
| Alkermes, Inc.Aristada | $11 | $67,50219 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $167 | $37,09123 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $34 | $28,98262 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 393 psychiatric/mental health providers in Utah.
Other psychiatric/mental health in Orem
- Lisa OlsenOrem$5K
- Deven JenningsOrem$3K
- Karl TuckerOrem$3K
- Bret HafenLayton$381K
- Alberto SouzaSaint George$114K
- Debra HainRiverton$29K
- Kristin BarberSalt Lake City$28K
- Briana TerrySalt Lake City$14K
- Paige MarshallSaint George$13K
- Derick MoodySpringville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.